CRISPR Therapeutics AG (CRSP) closed at $39.41 in the latest trading session, marking a -0.76% move from the prior day.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events (including everything from Summerfest to the Milwaukee Film Festival), access ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...

Chinese battery giant CATL has reopened its lithium lepidolite mine and refinery in Jiangxi province, a spokesperson for its ...